Novo Nordisk has launched its anti-obesity drug Wegovy in India, which has become a key market for the company. Having ...

As of 2024, Brazil's Semaglutide market was estimated at $581 million. The global market size for the GLP-1 (glucagon-like ...

Experts say supplement companies have tried to capitalize on the GLP-1 craze, putting the phrase in their product names, ...

Current health news covers Roche's Alzheimer's drug research, UnitedHealth's leadership hopes, Nordic Capital's ...

Ozempic and its counterparts, including Wegovy, Mounjaro and Zepbound, have surged in popularity as a means for weight loss, fueled by celebrity endorsements and slick pharmaceutical marketing.

Tempus AI surges 91.8% YTD with soaring genomics revenues and a $200M AstraZeneca deal, outpacing NVIDIA in AI healthcare gains.

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Ozempic (semaglutide) and other GLP-1 medications have helped many people lose weight and manage chronic conditions like type ...

The pact, announced on Sunday at Donald Trump’s golf resort in Turnberry, Scotland, imposes a 15 per cent import tariff on ...

The US struck a framework trade agreement with the European Union on Sunday, imposing a 15-percent import tariff on most EU goods — half the threatened rate — and averting a bigger trade war between ...

A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will ...

Questions, critiques and discrepancies are hanging over the framework agreement, but investors seem to view it as a win all ...